Treatment of rheumatoid arthritis with gammalinolenic acid


Ann Intern Med. – 1993 Nov 1;119(9):867-73. Leventhal LJ, Boyce EG, Zurier RB. University of Pennsylvania, Graduate Hospital, Presbyterian Medical Center, Philadelphia.


Treatment with gamma-linolenic acid resulted in clinically important reduction in the signs and symptoms of disease activity in patients with rheumatoid arthritis (P < 0.05). In contrast, patients given a placebo showed no change or showed worsening of disease. Gamma-linolenic acid reduced the number of tender joints by 36%, the tender joint score by 45%, swollen joint count by 28%, and the swollen joint score by 41%, whereas the placebo group did not show significant improvement in any measure. Overall clinical responses (significant change in four measures) were also better in the treatment group (P < 0.05). No patients withdrew from gamma-linolenic acid treatment because of adverse reactions.